natgillin/translations-raw huggingface dataset:
The immune system will then be able to produce antibodies more quickly and in large numbers when it comes into contact with the virus again. 
Ob ponovni izpostavitvi virusu jih bo imunski sistem tako lahko tvoril hitreje in več.
Since Pandemic influenza vaccine H5N1 AstraZeneca has been granted a conditional approval, the company that markets Pandemic influenza vaccine H5N1 AstraZeneca will conduct studies to gather more information on its effectiveness and side effects during its use in a pandemic as well as its shelf life. 
Ker je cepivo proti pandemski gripi H5N1 AstraZeneca pridobilo pogojno dovoljenje za promet, bo družba, ki ga trži, izvedla študije, v katerih bo zbrala več informacij o njegovi učinkovitosti in neželenih učinkih pri uporabi med pandemijo ter roku uporabnosti.
This showed that antibodies against Pandemic influenza vaccine H5N1 AstraZeneca increased substantially when vaccinated adults came into contact with the virus again. 
To je dokaz, da je pri uporabi cepiva proti pandemski gripi H5N1 AstraZeneca nastalo bistveno več protiteles, kadar so bili cepljeni odrasli ponovno izpostavljeni virusu.
The name of the medicine was changed to Pandemic influenza vaccine H5N1 AstraZeneca on 24 May 2017. 
Ime zdravila je bilo 24. maja 2017 spremenjeno v cepivo proti pandemski gripi H5N1 AstraZeneca.
Although Pandemic influenza vaccine H5N1 AstraZeneca might increase wheezing in children aged 1 to 2 years, the risk is considered acceptable in a pandemic situation. 
Zaradi cepiva proti pandemski gripi H5N1 AstraZeneca je lahko pri otrocih, starih od enega do dveh let, pogostejše piskajoče dihanje, vendar je tveganje v primeru pandemije ocenjeno kot sprejemljivo.
Previously known as Pandemic influenza vaccine H5N1 MedImmune 
Prej znano kot cepivo proti pandemski gripi H5N1 MedImmune.
What measures are being taken to ensure the safe and effective use of Pandemic influenza vaccine H5N1 AstraZeneca? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe cepiva proti pandemski gripi H5N1 AstraZeneca?
Pandemic influenza vaccine H5N1 AstraZeneca is a pandemic preparedness vaccine. 
Cepivo proti pandemski gripi H5N1 AstraZeneca je cepivo za pripravljenost na pandemijo.
However, a second vaccine that acts in a different way is able to make antibodies that can be measured easily. 
Preprosto pa je mogoče meriti nastanek protiteles, ki jih sproži drugo cepivo z drugačnim delovanjem.
For the full list of all side effects reported with Pandemic influenza vaccine H5N1 AstraZeneca, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi cepiva proti pandemski gripi H5N1 AstraZeneca, glejte navodilo za uporabo.
Pandemic influenza vaccine H5N1 AstraZeneca has been given ‘conditional approval'. 
Cepivo proti pandemski gripi H5N1 AstraZeneca je pridobilo „pogojno dovoljenje za promet“.
pandemic influenza vaccine (H5N1) (live attenuated, nasal) 
Cepivo proti pandemski gripi H5N1 AstraZeneca cepivo proti pandemski gripi (H5N1) (živo, oslabljeno, nazalno)
Other information about Pandemic influenza vaccine H5N1 AstraZeneca 
Druge informacije o cepivu proti pandemski gripi H5N1 AstraZeneca
What is Pandemic influenza vaccine H5N1 AstraZeneca and what is it used for? 
Kaj je cepivo proti pandemski gripi H5N1 AstraZeneca in za kaj se uporablja?
This is further supported by data in children given similar seasonal and pandemic live attenuated flu vaccines in large studies and in clinical practice. 
To pričakovanje podpirajo tudi podatki iz obsežnejših študij in klinične prakse o delovanju podobnih sezonskih in pandemskih živih, oslabljenih cepiv proti gripi pri otrocih.
What benefits of Pandemic influenza vaccine H5N1 AstraZeneca have been shown in studies? 
Kakšne koristi je cepivo proti pandemski gripi H5N1 AstraZeneca izkazalo v študijah?
The vaccine is expected to protect children against pandemic flu, on the basis of data obtained with this vaccine in adults. 
Na podlagi podatkov, ki so bili pridobljeni pri odraslih, se pričakuje, da bo cepivo otroke zaščitilo pred pandemsko gripo.
Further studies on the effects on the vaccine in children will need to be provided once the the flu strain causing the pandemic is included in the vaccine. 
Ko bo v cepivo vključen sev gripe, ki bo vzrok pandemije, bo treba predložiti dodatne študije učinkov cepiva pri otrocih.
What are the risks associated with Pandemic influenza vaccine H5N1 AstraZeneca? 
Kakšna tveganja so povezana s cepivom proti pandemski gripi H5N1 AstraZeneca?
Why is Pandemic influenza vaccine H5N1 AstraZeneca approved? 
Zakaj je bilo cepivo proti pandemski gripi H5N1 AstraZeneca odobreno?
The dose is one spray (0.1 ml) into each nostril. 
Cepivo proti pandemski gripi H5N1 AstraZeneca je na voljo v obliki pršila za nos. Odmerek je en vpih (0,1 ml) v vsako nosnico.
What information is still awaited for Pandemic influenza vaccine H5N1 AstraZeneca? 
Katere informacije o cepivu proti pandemski gripi H5N1 AstraZeneca še pričakujemo?
How does Pandemic influenza vaccine H5N1 AstraZeneca work? 
Kako cepivo proti pandemski gripi H5N1 AstraZeneca deluje?
How is Pandemic influenza vaccine H5N1 AstraZeneca used? 
Kako se cepivo proti pandemski gripi H5N1 AstraZeneca uporablja?
• hypertension; 
• hipertenzijo;
Plendil has been approved through national procedures in the following countries in the European Economic Area (EEA): Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden and the United Kingdom. 
Zdravilo Plendil je bilo z nacionalnimi postopki odobreno v naslednjih državah v Evropskem gospodarskem prostoru (EGP): Avstriji, Belgiji, Bolgariji, Hrvaški, Cipru, Češki republiki, Danski, Estoniji, Finski, Franciji, Nemčiji, Grčiji, Madžarski, Islandiji, Irski, Italiji, Latviji, Litvi, Luksemburgu, Malti, Nizozemski, Norveški, Poljski, Portugalski, Romuniji, Slovaški, Španiji, Švedski in Združenem Kraljestvu.
These changes were agreed accordingly. 
Te spremembe so bile soglasno odobrene.
The following wording was agreed: 
Dogovorjeno je bilo naslednje besedilo:
This formulation was available until 1994, though only launched in Australia. 
Ta formulacija je bila na voljo do leta 1994, vendar se je tržila samo v Avstraliji.
Therefore such combinations should be avoided (see section 4.5).' 
Posledično se je treba tem kombinacijam izogibati (glejte poglavje 4.5).
Overall summary of the scientific evaluation of Plendil and associated names (see Annex I) 
Splošni povzetek znanstvenega vrednotenja zdravila Plendil in povezanih imen (glejte Prilogo I)
The prolonged release tablet is available in three tablet strengths 2.5mg, 5mg and 10mg. 
Tableta s podaljšanim sproščanjem je na voljo v treh jakostih: 2,5 mg, 5 mg in 10 mg.
• stable angina pectoris. 
• stabilno angino pektoris.
The CHMP requested some additional wordings. 
Odbor CHMP je predlagal nekaj dodatnega besedila.
The CHMP therefore considers it necessary to include the following text in Section 4.4, including a reference to Section 4.5: 
Odbor CHMP zato meni, da je treba v poglavje 4.4, vključno z referenco na poglavje 4.5, vključiti naslednje besedilo:
− UK/W/002/pdWS/001 Article 45 Paediatric Workshare, finalised 15 October 2009. 
− UK/W/002/pdWS/001, člen 45, Paediatric Workshare, zaključeno 15. oktobra 2009;
This method generates the Empirical Bayesian Geometric Mean (EBGM) with a 90% confidence interval (EB05 to EB95). 
Bayesovo geometrično povprečje (EBGM) z 90-odstotnim intervalom zaupanja (EB05 do EB95).
In Europe, the prolonged release tablet was first approved in December 1987 and was first launched in Denmark in 1988. 
V Evropi je bila tableta s podaljšanim sproščanjem prvič odobrena decembra 1987, prvič pa so je dali v promet na Danskem leta 1988.
The divergences were due to differences in the indication, recommendation in maximum daily dose and down titration. 
Razhajanja so bila posledica razlik v indikaciji, priporočilu za največji dnevni odmerek in postopnem zmanjševanju odmerka.
For the indication “stable angina pectoris” there were several divergences. 
Pri indikaciji „stabilna angina pektoris“ je bilo več razhajanj.
Today, Plendil is available worldwide for oral administration as a prolonged release tablet (except in Japan where another immediate release tablet is marketed). 
Danes je zdravilo Plendil na voljo po celem svetu za peroralno uporabo v obliki tablete s podaljšanim sproščanjem (razen na Japonskem, kjer je v prometu druga tableta s takojšnjim sproščanjem).
If patients taking felodipine suffer from headache, nausea, dizziness or fatigue the ability to react may be impaired. 
Če se pri bolniku, ki jemlje felodipin, pojavijo glavobol, navzea, omotica ali utrujenost, je lahko sposobnost reagiranja poslabšana.
Section 4.1 - Therapeutic Indications Plendil is indicated for: 
Poglavje 4.1 - Terapevtske indikacije Zdravilo Plendil je indicirano za:
The European Commission notified the European Medicines Agency/ Committee for Medicinal Products for Human Use (EMA/CHMP) secretariat of an official referral under Article 30 of Directive 2001/83/EC in order to resolve divergences amongst the nationally authorised product information (PI) for the above-mentioned products and thus to harmonise them across the EU. 
Evropska komisija je Evropsko agencijo za zdravila/Odbor za zdravila za uporabo v humani medicini (EMA/CHMP) obvestila o uradni napotitvi v skladu s členom 30 Direktive 2001/83/ES, z namenom odprave razlik med nacionalno odobrenimi informacijami o zdravilu za zgoraj navedena zdravila in uskladitve teh informacij po vsej EU.
The MAH considered an EB05 >1.8 a possible signal i.e. the event is reported disproportional often in association with that drug. 
Imetnik dovoljenja za promet je vrednost EB05 > 1,8 obravnaval kot morebitni signal, tj. o dogodku poročajo nesorazmerno pogosto v povezavi z zdravilom.
However, outside the referenced trials, no significant publication have been found, limiting the total reported material on felodipine use in vasospastic angina to around 30 patients. 
Vendar razen navedenih preskušanj ni bilo mogoče najti nobene pomembne publikacije, kar je omejilo skupno gradivo, s katerim so poročali o uporabi felodipina pri vazospastični angini, na približno 30 bolnikov.
The final agreed wording is as follows: ‘Felodipine should not be given during pregnancy. 
Dogovorjeno je bilo naslednje končno besedilo: „Felodipin se ne sme uporabljati med nosečnostjo.
When taken in therapeutic doses by the nursing mother it is, however, not likely to affect the infant”. 
Kadar pa ga mater jemlje v terapevtskih odmerkih, ni verjetno, da bo vplival na dojenčka“.
The wording for hypertension was divergent in all EU MSs. 
Besedilo za hipertenzijo je bilo različno v vseh državah članicah EU.
Plendil can also be used in the treatment of vasospastic (Prinzmetal's) angina”. 
Zdravilo Plendil se lahko uporablja tudi za zdravljenje vazospastične (Prinzmetalove) angine“.
The proposal for the harmonised EU SmPC is based on the CPS from 2011 and CDS from October 2012. 
Predlog za usklajeni povzetek glavnih značilnosti zdravila v EU temelji na ključnem varnostnem profilu iz leta 2011 in CDS iz oktobra 2012.
There were also discrepancies regarding recommendations for special population groups namely elderly and paediatric, renal and hepatic impairment, administration with/ without food. 
Prisotna so bila tudi odstopanja glede priporočil za posebne skupine bolnikov, tj. starejši in pediatrični bolniki, okvara ledvic ter jeter, dajanje skupaj s hrano/brez nje.
There are no data on the effects of felodipine on patient fertility. 
Podatkov o učinkih felodipina na bolnikovo plodnost ni.
Plendil was originally approved for marketing in Denmark on 16 March 1987, as an immediate release tablet. 
Prvo dovoljenje za promet z zdravilom Plendil je bilo odobreno 16. marca 1987 na Danskem v obliki tablete s takojšnjim sproščanjem.
Some MSs were missing a text referring to absorption, distribution, metabolism and elimination. 
V nekaterih državah članicah je manjkalo besedilo, povezano z absorpcijo, porazdelitvijo, presnovo in izločanjem.
The results of the conducted studies on felodipine in vasospastic angina show an effect on the condition, as there are improvements in angina symptoms and reductions or disappearance of transient ST-segment elevations at hyperventilation or systemic ergonovine provocation. 
Rezultati opravljenih študij s felodipinom pri vazospastični angini kažejo učinek na to stanje, saj je prišlo do izboljšanja simptomov angine in zmanjšanja ali izginotja prehodnega povečanja segmenta ST pri hiperventilaciji ali sistemski provokaciji z ergonovinom.
It is expected that the patient has been informed to seek medical advice in that situation, and that all aspects of therapies are considered, included actions to be taken regarding discontinuation of felodipine treatment. 
Pričakovano je, da je bila bolnica obveščena, naj se v takih okoliščinah posvetuje z zdravnikom, in da so bili upoštevani vsi vidiki zdravljenja, vključno z ukrepi, ki jih je treba uvesti glede prekinitve zdravljenja s felodipinom.
The wording on section 4.8 was divergent. 
Besedila v poglavju 4.8 so se razlikovala.
Section 4.6 - Fertility, pregnancy and lactation The wording in section 4.6 was divergent. 
Poglavje 4.6 - Plodnost, nosečnost in dojenje Besedila v poglavju 4.6 so se razlikovala.
Felodipine is a dihydropyridine-type calcium channel blocker (calcium antagonist) and is indicated for the control of hypertension and in many countries also for the treatment of stable angina pectoris. 
Felodipin je dihidropiridinski blokator kalcijevih kanalčkov (kalcijev antagonist) in je indiciran za nadzorovanje hipertenzije, v mnogih državah pa tudi za zdravljenje stabilne angine pektoris.
Three European procedures have been completed leading to agreed wording in Plendil Summary of Product Characteristics (SmPCs): 
Zaključili so se trije evropski postopki, s katerimi se je poenotilo besedilo v povzetkih glavnih značilnosti zdravila Plendil:
Modifications relate to deletion of unnecessary and outdated wording, table format and addition of Hypotension as an adverse drug reaction (ADR). 
Spremembe so povezane z izbrisom nepotrebnih in zastarelih besedil, obliko preglednice in dodajanjem hipotenzije kot neželenega učinka na zdravilo.
‘Concomitant administration of drugs that strongly induce or inhibit CYP3 A4 enzymes result in extensively decreased or increased plasma levels of felodipine, respectively. 
„Sočasna uporaba zdravil, ki močno inducirajo ali zavirajo encime CYP3A4, povzroča zelo znižane oziroma zvišane ravni felodipina v plazmi.
The findings in the reproduction studies do not demonstrate evidence of direct fetotoxicity. 
Ugotovitve študij razmnoževanja niso pokazale dokazov glede neposredne toksičnosti za plod.
Searches were also conducted in the FDA Adverse Event Reporting System (AERS) database and in the WHO Vigibase database. 
Opravili so tudi iskanje po naboru podatkov v Sistemu za poročanje neželenih dogodkov (AERS) urada FDA in naboru podatkov Vigibase organizacije SZO.
Overall, the statement of grounds for not including adverse events included in one or few national texts is considered acceptable by the CHMP. 
Na splošno je odbor CHMP menil, da je izjava o podlagi za izključitev neželenih dogodkov, vključenih v eno ali več nacionalnih besedil, sprejemljiva.
− SK/H/PSUR/0006/001, PSUR (01 Jan 2007 to 31 Dec 2009), finalised 20 October 2011 with agreed Core Safety Profile (CSP). 
− SK/H/PSUR/0006/001, PSUR (1. januar 2007 do 31. december 2009), zaključeno 20. oktobra 2011 z dogovorjenim ključnim varnostnim profilom (CSP);
− SK/H/PSUR/0006/002, PSUR (01 Jan 2010 to 31 Dec 2012), finalised 4 December 2013 and where no changes to the Product Information were proposed. 
− SK/H/PSUR/0006/002, PSUR (1. januar 2010 do 31. december 2012), zaključeno 4. decembra 2013; predlagane niso bile nobene spremembe informacij o zdravilu.
The CHMP asked the MAH to insert statements regarding interactions leading increased plasma concentration of felodipine and interactions leading to decreased plasma concentration of felodipine. 
Odbor CHMP je imetnika dovoljenja za promet z zdravilom zaprosil, naj vključi izjave glede interakcij, ki povzročajo povečano koncentracijo felodipina v plazmi, in interakcij, ki povzročajo zmanjšano koncentracijo felodipina v plazmi.
A pre-referral meeting between the EMA and marketing authorisation holder (MAH) was held on 14 October 2013. 
Agencija EMA in imetnik dovoljenja za promet z zdravilom sta se 14. oktobra 2013 sestala na prednapotitveni seji.
Due to the divergent national decisions taken by Member States (MS) concerning the authorisation of Plendil and its associated names, these products were included in the list of products for SmPC harmonisation, requested by the Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh). 
Zaradi razhajajočih nacionalnih odločitev držav članic glede odobritve zdravila Plendil in povezanih imen so bila ta zdravila vključena na seznam zdravil za uskladitev povzetka glavnih značilnosti zdravila, ki jo je zahtevala Usklajevalna skupina za postopke z medsebojnim priznavanjem in decentralizirane postopke - zdravila za uporabo v humani medicini (CMDh).
Data on the efficacy and safety of specifically felodipine in this indication are very scarce and the MAH did not discuss the extrapolability of the results obtained with other dihydropyridines in this indication. 
Podatki o učinkovitosti in varnosti, ki se specifično nanašajo na felodipin pri tej indikaciji, so zelo redki in imetnik dovoljenja za promet z zdravilom ni ekstrapoliral rezultatov, pridobljenih z drugimi dihidropiridini za to indikacijo.
The total published experience of felodipine in vasospastic angina pectoris and the accumulated safety information is too limited to define a robust benefit risk ratio. 
Skupne objavljene izkušnje glede felodipina pri vazospastični angini pektoris in zbrani varnostni podatki so preveč omejeni, da bi lahko določili zanesljivo razmerje med tveganji in koristmi.
Section 4.7 - Effects on ability to drive and use machines The CHMP proposed an alternative text in line with amlodipine harmonised SmPC for this section: “Felodipine can have minor or moderate influence on the ability to drive and use machines. 
Poglavje 4.7 - Vpliv na sposobnost vožnje in upravljanja s stroji Odbor CHMP je v skladu z usklajenim povzetkom glavnih značilnosti zdravila za amlodipin predlagal spremembo besedila v tem poglavju: „Felodipin ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
the CHMP has recommended the variation to the terms of the marketing authorisations for which the summary of product characteristics, labelling and package leaflet are set out in Annex III for Plendil and associated names (see Annex I). 
je odbor CHMP priporočil spremembo pogojev dovoljenj za promet z zdravilom, za katera so povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo podani v Prilogi III za zdravilo Plendil in povezana imena (glejte Prilogo I).
In conclusion, based on the assessment of the MAH proposal and responses and following the discussions of the Committee, the CHMP adopted harmonised sets of Product Information documents of Plendil and associated names. 
V zaključku je CHMP na podlagi ocene predloga imetnika dovoljenja za promet z zdravilom in odgovorov ter po razpravi odbora potrdil usklajene sklope dokumentov z informacijami o zdravilu Plendil in povezana imena.
The CHMP asked the MAH to comment on the following contraindications: stroke in the past 6 months, Hypertrophic cardiomyopathy, Atrioventricular block grade 2 and 3, Severe renal impairment (GFR <30 ml/min, creatinine > 1.8 mg/dl), Severe hepatic impairment/liver cirrhosis, Breast-feeding women/breast feeding infants and treatment with calcium channel blockers. 
Odbor CHMP je imetnika dovoljenja za promet z zdravilom zaprosil, naj poda mnenje glede naslednjih kontraindikacij: možganska kap v zadnjih 6 mesecih, hipertrofična kardiomiopatija, atrioventrikularni blok stadija 2 in 3, huda okvara ledvic (GFR < 30 ml/min, kreatinin > 1,8 mg/dl), huda okvara jeter/jetrna ciroza, doječe matere/dojenci in zdravljenje z blokatorji kalcijevih kanalčkov.
In a nonclinical reproductive study in the rat (see section 5.3), there were effects on fetal development but no effect on fertility at doses approximating to therapeutic. 
V predkliničnih študijah razmnoževanja na podganah (glejte poglavje 5.3) so ugotovili učinke na razvoj ploda, pri odmerkih, podobnim terapevtskim, pa ni bilo nobenega učinka na plodnost.
The MAH included the information regarding the preclinical data, and subsequent text added to state that it cannot be stated with certainty that the pharmacological effects are not relevant for humans. 
Imetnik dovoljenja za promet z zdravilom je vključil informacije, povezane s predkliničnimi podatki, in dodal posledično besedilo, da ni mogoče zagotovo izjaviti, da farmakološki učinki niso pomembni za človeka.
Besides a warning that ‘The efficacy and safety of felodipine in the treatment of hypertensive emergencies has not been studied' was also be included in view of the missing evidence with felodipine in hypertensive emergencies and to be in agreement with the product information of amlodipine the Rapporteurs see the need to include the warning as proposed in the LoOI. 
Poleg opozorila „Varnosti in učinkovitosti felodipina pri zdravljenju nujnih primerov hipertenzije niso proučevali“, so poročevalci zaradi manjkajočih dokazov glede uporabe felodipina v nujnih primerih hipertenzije in skladnosti z informacijami o zdravilu za amlodipin izpostavili potrebo po vključitvi opozorila, kot je bil predlagan na seznamu nerešenih vprašanj.
Some MSs were missing text from the CSP and some MSs had different text. 
V nekaterih državah članicah je manjkalo besedilo iz ključnega varnostnega profila, nekatere pa so imele različna besedila.
The MAH justified the deletion of ADRs using the Empirical Bayesian Data Mining techniques to compute disproportionality scores from the MAH's global safety database. 
Imetnik dovoljenja za promet z zdravilom je izbris neželenih učinkov na zdravilo upravičil z empiričnimi Bayesovimi tehnikami rudarjenja podatkov, s katerimi je izračunal nesorazmernost na podlagi svoje globalne zbirke podatkov o varnosti.
• the scope of the referral was the harmonisation of the Summary of Products Characteristics, labelling and package leaflet, 
• namen napotitve je bila uskladitev povzetkov glavnih značilnosti zdravila, označevanja in navodil za uporabo;
The MAH agreed and included that ‘Plendil contains castor oil, which can cause stomach upset and diarrhoea'. 
Imetnik dovoljenja za promet z zdravilom se je strinjal in vključil besedilo: „Zdravilo Plendil vsebuje ricinusovo olje, ki lahko povzroči razdražen želodec in drisko.“
The different MSs had “stable angina pectoris and vasospastic angina (variant of Prinzmetal's angina)”, “Prophylaxis of angina pectoris (stable and vasospastic forms)”, “Angina pectoris” and “Stable exertional angina pectoris; Plendil can be given as monotherapy or can be combined with a beta blocker. 
Različne države članice so imele besedila „stabilna angina pektoris in vazospastična angina (različica Prinzmetalove angine)“, „profilaksa proti angini pektoris (stabilnim in vazospastičnim oblikam)“, „angina pektoris“ in „stabilna angina pektoris ob naporu; zdravilo Plendil se lahko uporablja kot monoterapija ali v kombinaciji z betaadrenergičnim antagonistom.
Finally the CHMP requested the MAH to add a warning on castor oil. 
Na koncu je odbor CHMP imetniku dovoljenja za promet z zdravilom naročil, naj doda opozorilo glede ricinusovega olja.